Archives of dermatology最新文献

{"title":"A nodule on the upper eyelid-quiz case.","authors":"Ben A Esdaile, Robert Almeyda, Olivia Espinosa de Los Monteros, Richard Turner, Jonathan C Bowling","doi":"10.1001/archderm.148.12.1411-d","DOIUrl":"https://doi.org/10.1001/archderm.148.12.1411-d","url":null,"abstract":"","PeriodicalId":8175,"journal":{"name":"Archives of dermatology","volume":"148 12","pages":"1411-6"},"PeriodicalIF":0.0,"publicationDate":"2012-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1001/archderm.148.12.1411-d","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"31129436","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The utility of a portable video player in wart removal.","authors":"Divya Seshadri, Siddharth Sarkar","doi":"10.1001/2013.jamadermatol.215","DOIUrl":"https://doi.org/10.1001/2013.jamadermatol.215","url":null,"abstract":"","PeriodicalId":8175,"journal":{"name":"Archives of dermatology","volume":"148 12","pages":"1425-6; author reply 1426-7"},"PeriodicalIF":0.0,"publicationDate":"2012-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1001/2013.jamadermatol.215","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"31128825","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Successful treatment of recurrent idiopathic plantar eccrine hidradenitis with colchicine.","authors":"Helene Sophie Scheer, Jivko Kamarashev, Lisa Weibel","doi":"10.1001/archdermatol.2012.2221","DOIUrl":"https://doi.org/10.1001/archdermatol.2012.2221","url":null,"abstract":"","PeriodicalId":8175,"journal":{"name":"Archives of dermatology","volume":"148 12","pages":"1357-9"},"PeriodicalIF":0.0,"publicationDate":"2012-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1001/archdermatol.2012.2221","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"31129431","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A new spectrum of skin toxic effects associated with the multikinase inhibitor vandetanib.","authors":"Damien Giacchero, Constanza Ramacciotti, Jean Philippe Arnault, Maryse Brassard, Eric Baudin, Laurent Maksimovic, Christine Mateus, Gorana Tomasic, Janine Wechsler, Martin Schlumberger, Caroline Robert","doi":"10.1001/2013.jamadermatol.192","DOIUrl":"https://doi.org/10.1001/2013.jamadermatol.192","url":null,"abstract":"S kin manifestations are among the most frequent adverse effects of targeted therapies. Hyperkeratosis and hand-foot skin reaction are observed with most raf and vascular endothelial growth factor (VEGF) inhibitors, whereas folliculitis is a hallmark of epidermal growth factor receptor (EGFR) blocking agents. Vandetanib (Zactima, ZD6474; AstraZeneca) is a multikinase inhibitor that targets EGFR, VEGF receptors 1, 2, and 3 and the RET (rearranged during transfection) receptor.","PeriodicalId":8175,"journal":{"name":"Archives of dermatology","volume":"148 12","pages":"1418-20"},"PeriodicalIF":0.0,"publicationDate":"2012-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1001/2013.jamadermatol.192","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"31128821","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A variant of AESOP syndrome (adenopathy and extensive skin patch overlying a plasmacytoma) in a malignant blue-cell tumor.","authors":"Chong Wee Foo, Scott R Florell, Marta J Petersen","doi":"10.1001/archdermatol.2012.2858","DOIUrl":"https://doi.org/10.1001/archdermatol.2012.2858","url":null,"abstract":"2006;332(6):339-345. 3. Weedon D. Weedon’s Skin Pathology. 3rd ed. Philadelphia, PA: Churchill Livingston; 2010. 4. Hassan Z, Mullins RF, Friedman BC, Shaver JR, Alam B, Mian MA. Purpura fulminans: a case series managed at a regional burn center. J Burn Care Res. 2008;29(2):411-415. 5. Darmstadt GL. Acute infectious purpura fulminans: pathogenesis and medical management. Pediatr Dermatol. 1998;15(3):169-183.","PeriodicalId":8175,"journal":{"name":"Archives of dermatology","volume":"148 12","pages":"1431-2"},"PeriodicalIF":0.0,"publicationDate":"2012-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1001/archdermatol.2012.2858","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"31128829","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clinical and sociodemographic characteristics associated with thick melanomas. A population-based, case-case study in France.","authors":"Florent Grange,&nbsp;Coralie Barbe,&nbsp;Francois Aubin,&nbsp;Dan Lipsker,&nbsp;Florence Granel-Brocard,&nbsp;Michel Velten,&nbsp;Sophie Dalac,&nbsp;François Truchetet,&nbsp;Catherine Michel,&nbsp;Audrey Mitschler,&nbsp;Gwendoline Arnoult,&nbsp;Antoine Buemi,&nbsp;Stéphane Dalle,&nbsp;Philippe Bernard,&nbsp;Anne-Sophie Woronoff","doi":"10.1001/archdermatol.2012.2937","DOIUrl":"https://doi.org/10.1001/archdermatol.2012.2937","url":null,"abstract":"<p><strong>Objective: </strong>To identify clinical and sociodemographic factors associated with very thick melanoma (VTM) (Breslow thickness, 3 mm) in France.</p><p><strong>Design: </strong>Retrospective, population-based, case-case study using a survey of cancer registries and questionnaires to practitioners.</p><p><strong>Setting: </strong>Five regions covering 19.2% of the French territory and 8.2 million inhabitants.</p><p><strong>Cases: </strong>Cases included all incident melanomas with a Breslow thickness of 3 mm or greater (ie, VTM), diagnosed between January 1 and December 31, 2008, in residents of the study area (Alsace, Bourgogne, Champagne-Ardenne, Franche-Comte', and Lorraine, France), and a randomly selected sample of melanomas thinner than 3 mm.</p><p><strong>Main outcome measures: </strong>Circumstances of diagnosis,clinical and pathological characteristics of melanomas,and sociodemographic characteristics of patients(age, sex, residence, home and family life conditions, educational level, and smoking habits).</p><p><strong>Results: </strong>Among 898 melanomas, 149 (16.6%) were VTMs. Very thick melanomas were more often diagnosed in a general-practice setting than thinner melanomas.The rate of immediate clinical recognition by dermatologists was lower for VTMs than for thinner melanomas. In a multivariate logistic regression analysis,factors associated with VTM were the nodular and acrolentiginous types; the head and neck and lower limb locations; older age; male sex; and being single, separated,divorced, or widowed. When only factors related to patients were taken into account, older age, male sex,and living alone were independent risk factors for VTM.The most significant risk was observed for patients living alone.</p><p><strong>Conclusions: </strong>Intrinsic factors related to the tumor and socio demographic characteristics of patients contribute to the occurrence of VTM. These factors should be better targeted in future secondary prevention programs.</p>","PeriodicalId":8175,"journal":{"name":"Archives of dermatology","volume":"148 12","pages":"1370-6"},"PeriodicalIF":0.0,"publicationDate":"2012-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1001/archdermatol.2012.2937","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"30913827","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Gefitinib-induced paronychia: response to autologous platelet-rich plasma.","authors":"Soon-Hyo Kwon,&nbsp;Jae-Woo Choi,&nbsp;Jong-Soo Hong,&nbsp;Sang-Young Byun,&nbsp;Kyoung-Chan Park,&nbsp;Sang-Woong Youn,&nbsp;Chang-Hun Huh,&nbsp;Jung-Im Na","doi":"10.1001/archdermatol.2012.3022","DOIUrl":"https://doi.org/10.1001/archdermatol.2012.3022","url":null,"abstract":"<p><strong>Background: </strong>Paronychia has been reported in as many as 10% of patients treated with gefitinib. Although conservative management and treatment with topical or systemic antibiotics are beneficial, no effective method exists for intractable cases. Platelet-rich plasma (PRP)consists of a high concentration of platelets that promote wound healing through chemotaxis, cell proliferation,angiogenesis, and tissue remodeling.</p><p><strong>Observations: </strong>We herein report a refractory case of gefitinib-induced paronychia successfully treated with autologous PRP. A 68-year-old woman who had been diagnosed as having lung adenocarcinoma with multiple bone and brain metastases initiated gefitinib therapy at an oral dose of 250 mg/d. After 1 month, multiple paronychia with periungual granulation appeared on the nailfold of the first, second, and third toenails of both feet.Because the paronychia recurred repeatedly despite use of a topical antibiotic, topical corticosteroid, and short term systemic antibiotic, she started PRP treatment. After 3 months, the lesion showed marked improvement with minimal pain or discharge.</p><p><strong>Conclusion: </strong>This case highlights the therapeutic challenges of using PRP to promote tissue repair in intractable gefitinib-induced paronychia and merits further investigation.</p>","PeriodicalId":8175,"journal":{"name":"Archives of dermatology","volume":"148 12","pages":"1399-402"},"PeriodicalIF":0.0,"publicationDate":"2012-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1001/archdermatol.2012.3022","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"30913841","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Removal of tattoos by q-switched laser: variables influencing outcome and sequelae in a large cohort of treated patients.","authors":"Pier Luca Bencini,&nbsp;Simone Cazzaniga,&nbsp;Athanasia Tourlaki,&nbsp;Michela Gianna Galimberti,&nbsp;Luigi Naldi","doi":"10.1001/archdermatol.2012.2946","DOIUrl":"https://doi.org/10.1001/archdermatol.2012.2946","url":null,"abstract":"<p><p>OBJECTIVE To analyze variables affecting the treatment course and prognosis of Q-switched laser tattoo removal. DESIGN Observational prospective cohort study. SETTING The study was carried out in a referral center for surgery and laser surgery in Milan. PARTICIPANTS Of 397 consecutive patients initially enrolled from January 1, 1995, to December 31, 2010, 352 patients (201 men and 151 women; median age, 30 years) were included in the analysis. INTERVENTION All patients were treated by the same investigator with Q-switched 1064/532-nm Nd:YAG laser and Q-switched 755-nm alexandrite laser according to tattoo colors. Laser sessions were scheduled at 6-week or longer intervals. MAIN OUTCOME MEASURES Successful therapy was defined as removal of the tattoo, with no adverse effects other than transient hypochromia or darkening. RESULTS The cumulative rates of patients with successful tattoo removal were 47.2% (95% CI, 41.8%-52.5%) after 10 sessions and 74.8% (95% CI, 68.9%-80.7%) after 15 sessions. Smoking, the presence of colors other than black and red, a tattoo larger than 30 cm2, a tattoo located on the feet or legs or older than 36 months, high color density, treatment intervals of 8 weeks or less, and development of a darkening phenomenon were associated with a reduced clinical response to treatment. CONCLUSIONS To our knowledge, this study is the first to formally assess prognostic factors for effective tattoo removal by Q-switched laser. Several variables influence response rates and should be considered when planning tattoo removal treatments.</p>","PeriodicalId":8175,"journal":{"name":"Archives of dermatology","volume":"148 12","pages":"1364-9"},"PeriodicalIF":0.0,"publicationDate":"2012-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1001/archdermatol.2012.2946","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"30913327","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Integrated positron-emission tomography and computed tomography manifestations of cutaneous T-cell lymphoma.","authors":"Maria R Kamstrup,&nbsp;Robert Gniadecki,&nbsp;Lars Friberg","doi":"10.1001/archdermatol.2012.3198","DOIUrl":"https://doi.org/10.1001/archdermatol.2012.3198","url":null,"abstract":"is highly suggestive of a UV-A–induced mechanism. Photosensitization is an adverse effect of many kinase inhibitors such as imatinib, sorafenib, and vemurafenib. Imatinib inhibits the adenosine triphosphate–dependent transporter ABCG2 resulting in intracellular porphyrin accumulation and phototoxic effects in vitro. Since vandetanib also inhibits the transporter activity of ABCG2, a similar porphyrin-induced mechanism might explain the similar effect. In a report of 2 cases, vandetanib-associated cutaneous pigmentation was preceded by photosensitization. In our more extensive experience, only half of the patients with cutaneous pigmentation had prior or concomitant skin photosensitization, making the hypothesis of post-photosensitization pigmentation less likely. In 3 patients, a multinucleated giant-cell granuloma was found in the dermis, which could result from a direct deposit of the drug in the skin. Vandetanib is being tested in the treatment of several types of cancers. In patients with medullary thyroid cancers, it has already demonstrated a significant efficacy, which led the US Food and Drug Administration and European Medicines Agency to label the drug for patients with advanced disease in 2011. Dermatologists should be aware of the spectrum of vandetanib toxic effects, and careful photoprotection should be used to facilitate compliance with treatment.","PeriodicalId":8175,"journal":{"name":"Archives of dermatology","volume":"148 12","pages":"1420-2"},"PeriodicalIF":0.0,"publicationDate":"2012-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1001/archdermatol.2012.3198","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"31128822","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Hidradenitis suppurativa, eruptive melanocytic nevi, and keratosis pilaris-like eruption in a patient treated with vemurafenib.","authors":"Liqiao Ma,&nbsp;Arturo R Dominguez,&nbsp;George R Collins,&nbsp;Kevin F Kia,&nbsp;Clay J Cockerell","doi":"10.1001/2013.jamadermatol.23","DOIUrl":"https://doi.org/10.1001/2013.jamadermatol.23","url":null,"abstract":"reportedusingcryotherapy, 5 wereportthiscasetoemphasizetheimportanceofrecognizingCAHandpursuingtreatmentowingtothepotentialforpremalignantchange.Furthermore,thesuccessofcryotherapysupportstheconcept that this condition may be due to an abnormal proliferation of keratinocytes. Presumably, cryotherapy may destroy the abnormal keratinocytes and allow for repopulation with normal epidermal cells, thereby eliminating the potential for malignant transformation in the future. This case demonstrates that cryotherapy is an efficacioustherapeuticoptionthatshouldbeconsideredforthe treatment of CAH. Furthermore it may eliminate the potential for progression to more serious cutaneous disease.","PeriodicalId":8175,"journal":{"name":"Archives of dermatology","volume":"148 12","pages":"1428-9"},"PeriodicalIF":0.0,"publicationDate":"2012-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1001/2013.jamadermatol.23","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"31128827","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}